MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction

Core Viewpoint - MIRA Pharmaceuticals has successfully completed the acquisition of SKNY Pharmaceuticals, enhancing its financial position and supporting its ongoing development programs [1] Financial Position - The acquisition included a contribution of $5 million in marketable securities from SKNY, which strengthens MIRA's balance sheet [1] Development Programs - The acquisition complements MIRA's advancing programs, specifically Ketamir-2 and MIRA-55, which focus on neurologic, neuropsychiatric, and metabolic disorders [1]